Apnimed, Inc.
APMD evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $1.15B
What it means
What to watch
Prepared research question
What matters most for APMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APMD
Apnimed is a late-stage clinical pharmaceutical company developing AD109 (Oxnimbi), an investigational oral therapy for obstructive sleep apnea, with an FDA PDUFA target action date of February 28, 2027.
Key risk: Single-product dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.15B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Apnimed, Inc..
Apnimed is a late-stage clinical pharmaceutical company developing AD109 (Oxnimbi), an investigational oral therapy for obstructive sleep apnea, with an FDA PDUFA target action date of February 28, 2027.
- Sole clinical product candidate is AD109 (Oxnimbi), a fixed-dose combination of aroxybutynin and atomoxetine for obstructive sleep apnea [sec_mda · as of 2026-07-27].
- FDA accepted the NDA for AD109 with a PDUFA target action date of February 28, 2027 [news · published 2026-09-08].
- Cash & equivalents of $172.8M as of 2026-06-30 [sec].
- Total revenue of $12.1M and net income of $125.9M as of 2026-06-30 [sec].
- Shareholders' equity was -$176.2M as of 2026-06-30 [sec].
What works
- Two registrational Phase 3 trials (SynAIRgy and LunAIRo) showed statistically significant reductions in apnea-hypopnea index vs placebo, with p<0.001 and p<0.0001 under different estimands [sec_mda · as of 2026-07-27].
- Oxnimbi was generally well-tolerated across both Phase 3 trials, with no drug-related serious adverse events reported [sec_mda · as of 2026-07-27].
- The company has a joint venture with Shionogi (SASS) to develop novel therapies for OSA and other sleep breathing disorders [sec_mda · as of 2026-07-27].
- If approved, Oxnimbi could become the first oral pharmacologic therapy targeting the neuromuscular root cause of upper airway collapse in OSA [news · published 2026-09-08].
What to weigh
- The company is entirely dependent on a single product candidate, Oxnimbi; failure to obtain approval or commercialize would materially harm the business [sec_mda · as of 2026-07-27].
- There is substantial doubt about the company's ability to continue as a going concern if additional capital cannot be raised [sec_mda · as of 2026-07-27].
- Shareholders' equity is deeply negative at -$176.2M as of 2026-06-30 [sec], indicating accumulated losses exceed contributed capital.
- No significant revenue is expected until at least 2027, even if Oxnimbi is approved, and substantial additional funding will be needed [sec_mda · as of 2026-07-27].
From the filings
Quoted directly from source documents.
Oxnimbi is the sole clinical product candidate and targets the neuromuscular defect of OSA.
“Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).”
SEC MD&A · July 27, 2026
FDA has set a PDUFA goal date of February 28, 2027.
“the FDA has issued a PDUFA goal date of February 28, 2027”
SEC MD&A · July 27, 2026
Phase 3 trials showed statistically significant reductions in AHI vs placebo.
“p<0.001 vs placebo), and under the on-treatment estimand by 60.5% and 58.2% (p<0.0001 vs placebo), in SynAIRgy and LunAIRo, respectively.”
SEC MD&A · July 27, 2026
There is substantial doubt about the company's ability to continue as a going concern.
“There is substantial doubt about our ability to continue as a going concern.”
SEC MD&A · July 27, 2026
Catalyst timeline
- 2021-11-29 · Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea — Initiation of Phase 2 dose-finding study for AD109 and AD504 combinations.
- 2023-09-16 · Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study) — Start of the SynAIRgy Phase 3 registrational trial for AD109.
- 2023-12-15 · The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial. - Apnea-hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3-27.2) — Readout of the MARIPOSA trial showing reduction in apnea-hypopnea index.
Risks & what to watch (4)›
Key risks
- Single-product dependency — Business relies entirely on Oxnimbi; failure in approval or commercialization would be materially harmful [sec_mda · as of 2026-07-27].
- Going concern uncertainty — Company has expressed substantial doubt about its ability to continue as a going concern without additional capital [sec_mda · as of 2026-07-27].
- Negative shareholders' equity — Shareholders' equity of -$176.2M as of 2026-06-30 indicates accumulated losses exceed contributed capital [sec].
- No near-term revenue — No significant revenue expected until at least 2027, even if Oxnimbi is approved [sec_mda · as of 2026-07-27].
What to watch
- FDA PDUFA decision on Oxnimbi by February 28, 2027 [news · published 2026-09-08].
- Company's ability to raise additional capital to fund operations and potential commercial launch [sec_mda · as of 2026-07-27].
- Progress of the joint venture with Shionogi (SASS) for additional sleep breathing disorder therapies [sec_mda · as of 2026-07-27].
- Any updates on post-approval commercialization plans or partnership agreements [sec_mda · as of 2026-07-27].
Sources: Catalysts · News · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Apnimed, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apnimed, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income $126M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Apnimed, Inc.?
Apnimed is a late-stage clinical pharmaceutical company developing AD109 (Oxnimbi), an investigational oral therapy for obstructive sleep apnea, with an FDA PDUFA target action date of February 28, 2027.
Who is the CEO of Apnimed, Inc.?
Mr. Kevin Robert Lind is the chief executive officer of Apnimed, Inc. (APMD).
Where is Apnimed, Inc. headquartered?
Apnimed, Inc. (APMD) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Apnimed, Inc. focus on?
Apnimed, Inc. develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.